Pyoderma Gangrenosum
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q3 2027.
- Q3 2027A Single-arm Open-label Study Assessing Short-term (Week 6, 16) and Long-term (Week 32) Efficacy of Guselkumab in Adult Participants With Pyoderma Gangrenosum
- Q4 2027A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy
Clinical MilestonesViewHide
- 2026-07-09A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic TherapyResults expected Q4 2027
- 2026-03-06A Single-arm Open-label Study Assessing Short-term (Week 6, 16) and Long-term (Week 32) Efficacy of Guselkumab in Adult Participants With Pyoderma GangrenosumResults expected Q3 2027
- 2026-07-09ClinicalA Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic TherapyResults expected Q4 2027
- 2026-03-06ClinicalA Single-arm Open-label Study Assessing Short-term (Week 6, 16) and Long-term (Week 32) Efficacy of Guselkumab in Adult Participants With Pyoderma GangrenosumResults expected Q3 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Pyoderma Gangrenosum2
- Dermatitis1
- Hidradenitis Suppurativa1
- Metabolic Syndrome1
Leading journals2
- American journal of clinical dermatology1
- Journal of the American Academy of Dermatology1
Leading researchers8
- Alavi A1
- Alhusayen R1
- Alikhan A1
- Daveluy SD1
- Delorme I1
- Garg A1
- Genovese G1
- Goldfarb N1
Affiliations (unnormalised)6
- Clinical Medical Library1
- College of Osteopathic Medicine1
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell1
- Duke University School of Medicine1
- Emory University School of Medicine1
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico1
Reference
Authoritative identity, definition & identifiers.
An idiopathic, rapidly evolving, and severely debilitating disease occurring most commonly in association with chronic ulcerative colitis. It is characterized by the presence of boggy, purplish ulcers with undermined borders, appearing mostly on the legs. The majority of cases are in people between 40 and 60 years old. Its etiology is unknown.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.